Tocilizumab

Tocilizumab Linked to Anemia Marker Improvement in Rheumatoid Arthritis

Tocilizumab Linked to Anemia Marker Improvement in Rheumatoid Arthritis

By

Tocilizumab was associated with significant improvements in hemoglobin and hematocrit over 2 years of treatment in patients with rheumatoid arthritis.

Guidelines for Biologics Use in Lupus by International Panel

Guidelines for Biologics Use in Lupus by International Panel

By

A multidisciplinary group of international experts has released recommendations for the use of biologics in patients with systemic lupus erythematosus.

Tocilizumab and Cardiovascular Risk in RA Patients

Tocilizumab and Cardiovascular Risk in RA Patients

No evidence was found of a higher cardiovascular risk among rheumatoid arthritis patients who switched from a different biologic drug or tofacitinib to tocilizumab vs to a tumor necrosis factor inhibitor.

Sign Up for Free e-Newsletters